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Background/Purpose: This study aims to describe the clinical characteristics and treatment outcome of
retinoblastoma in Mongolian children.
Methods: Data of all children diagnosed with retinoblastoma at the National Center for Maternal and
Child Health of Mongolia from 1987 to January 2014 were reviewed retrospectively. The ICRB classiﬁ-
cation was used. Survival characteristics of the cohort were analyzed.
Results: Retinoblastoma was diagnosed in 79 eyes of 64 cases during the study period. Median age of
diagnosis was 24.5 ± 15.8 months. There were no differences in sex ratio, and 15 cases (23%) were
bilateral. Forty-three (67%) patients were from rural areas. The more frequent clinical presentations were
leukocoria in 50 (78%) patients, strabismus in 24 (38%) patients, and glaucoma in 21 (33%) patients. Sixty-
one (95%) patients were diagnosed with Classiﬁcation D or worse when presented to us. Due to late
diagnosis in the majority of cases, unilateral and bilateral enucleations were performed in 48 (61%) eyes
and 24 (30%) eyes, respectively; exenteration was done in three (4%) eyes. Fifty-two (81%) patients
received chemotherapy and 13 (8.3%) patients underwent external beam radiation after enucleation. At
the time of last follow-up, 52 (81%) patients were alive, ﬁve (8%) patients were dead, and seven (11%)
patients had lost to follow-up or unknown vital status. The mean follow-up period was 121.5 months
(range, 12e360 months). In ﬁve cases with immunohistochemistry analysis in the eye specimen, neuron-
speciﬁc enolase-, Ki-67 protein-, and B-cell lymphoma 2-positive cells were found in all ﬁve (100%) cases
and Rb protein was detected in three (60%) cases.
Conclusion: Retinoblastoma in Mongolia is frequently diagnosed at late stages and has a poor outcome.
These data show the importance of early pediatric eye examinations and better treatment of retino-
blastoma in children younger than 3 years in Mongolia.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Retinoblastoma (RB) is a cancer of the very young; two-thirds
are diagnosed before 2 years of age and 95% before 5 years of age.
For these reasons, therapeutic approaches need to consider not
only the cure of the disease, but also the need to preserve visionts for any author.
ology, National Center for
n Street, Bayangol District,
at).
iety of Taiwan. Published by Elseviwith minimal long-term side effects. The estimated incidence of RB
is one in 16,000e18,000 births per year worldwide.1,2
Although RB is very curable when diagnosed early and treated
appropriately, the prognosis is poor when the basic elements in
diagnosis and treatment are lacking. Survival rates in the developed
world are very high, but the rates are much lower in developing
nations due to poor medical infrastructure, low alertness of parents
as well as pediatricians, and complex and deﬁcient socioeconomic
environments.3
In Mongolia, only three to four new cases of RB are estimated
each year. However, RB is an emerging health issue with problems
of late diagnosis and poor visual outcome.4 Although the countryer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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there is no system for collating such important data. There is a need
to review these situations and study survival of patients. This study
aims to describe the clinical characteristics and treatment outcome
of RB in Mongolian children.
2. Methods
Data of all children diagnosed with RB from 1987 to 2014 at the
National Center for Maternal and Child Health in Ulaanbaatar,
Mongolia were reviewed retrospectively with approval from the
Institutional Review Board of Mongolian National University of
Medical Science, Ulaanbaatar, Mongolia. The National Center for
Maternal and Child Health is the only referral tertiary-care level
hospital with a pediatric ophthalmology department. This depart-
ment is responsible for the whole country's pediatric eye care
services.
The data recorded included jurisdiction, sex, date of birth, age at
diagnosis, and information on laterality of tumor, family history of
RB, clinical presentations, and mode of treatment. The diagnosis of
RB was based on the results of slit-lamp examination, indirect
ophthalmoscopy, echography, computerized tomography, or mag-
netic resonance imaging, depending on the availability of the tools.
The International Classiﬁcation of RB was used.5
Enucleation and exenteration combined with systemic chemo-
therapy were treatments used for these patients. No other treat-
ment modalities such as laser, cryotherapy, selective ophthalmic
arterial chemotherapy, or intravitreal chemotherapy were available
at our center.
The 1-, 5-, 10-, 15-, and > 25-year survival rates of the cohort
were documented and analyzed.
2.1. Histologic and immunohistochemical assessments
With hematoxylin and eosin stain, the extent of tumor in optic
nerve, choroid, and anterior chamber was scored and conﬁrmed by
pathologists. The immunohistochemistry of RB was performed at
Beijing Tongren Hospital, Beijing, China. The expressed protein
checked in this study included RB protein, neuron-speciﬁc enolase
(NSE), s-100 protein, p53, vimentin, bcl-2, ki67, and glial ﬁbrillary
acidic protein.
2.2. Statistical analysis
The data of RB patients at our center from 1987 to 2014 were
collected and analyzed. The data were presented as descriptive
statistics. Patient survival was calculated and analyzed using the
KaplaneMeier method. Data were expressed as mean ± standard
deviation.
3. Results
3.1. Patients
Seventy-nine eyes of 64 children were diagnosed with RB at the
Department of Pediatric Ophthalmology in the National Center for
Maternal and Child Health from January 1987 to January 2014.
During this period, there were 2,081,930 newborns in Mongolia
according to statistics of health indicators, the Ministry of Health of
Mongolia. The incidence of RBwas about one in 32,000e33,000 live
births. Since the Pediatric Ophthalmology Department of the Na-
tional Center for Maternal and Child Health treats and takes care of
only RB patients in Mongolia, the estimation could represent the
whole country's estimation. The annual RB incidence between 1987
and 2013 varied from zero to 0.98 per 10,000 live births (Figure 1).Among these 64 patients, 43 (68%) were from rural areas and 21
(32%) from the capital city Ulaanbaatar.
3.2. Sex and laterality
There was equal sex distribution in our study; 32 (50%) were
boys and 32 (50%) were girls. In location, it was unilateral in 49
(77%) patients and bilateral in 15 (23%) patients. The disease was
familial in one (2%) patient and sporadic in 63 (98%) (Table 1).
3.3. Age at diagnosis
The age of diagnosis ranged from 1 month to 72 months. The
mean age of diagnosis was 24.5 ± 15.8 months. Fifty-three (83%)
patients were diagnosed before the age of 3 years. The age at
diagnosis was earlier in bilateral cases (mean age,
13.1 ± 12.8 months; range, 1e42 months) than in unilateral cases
(mean age, 28.1 ± 15 months; range, 1e72 months) (Table 1).
3.4. Presenting signs and stage
The most prevalent clinical conditions were as follows: leuko-
coria in 50 (78%) patients, strabismus in 24 (38%) patients, sec-
ondary glaucoma in 21 (33%) patients, hyphema in seven (11%)
patients, and orbital cellulitis in seven (11%) patients (Table 1).
Three (5%) patients presented with late-stage, extraocular exten-
sion of RB (Figure 2). Sixty-one (95%) patients were diagnosed with
Classiﬁcation Group D or worse when presented to us. Out of all the
eyes, 75 (95%) were diagnosed with Classiﬁcation Groups D and E,
two (2.5%) with Group B, and two (2.5%) with Group C.
3.5. Disease detection
Since there were no eye-screening programs in Mongolia, all
(100%) patients were referred to ophthalmologists for further
evaluation due to various presenting signs mentioned above.
Thirty-nine (60%) patients were examined with B scan, 38 (59%)
patients with computerized tomography, and 30 (46%) patients
with magnetic resonance imaging.
3.6. Spread of tumor
One (2%) case had intracranial extension, three (5%) cases had
extraocular extension, and one (2%) case developed orbital recur-
rence of RB 4 years after initial enucleation (Figure 3). The other
59 (92%) patients had intraocular RB without any extraocular
extension.
3.7. Secondary tumor and metastasis
None of our cases developed a secondary malignant neoplasm
before the cutoff date.
3.8. Mode of treatment
Enucleation of one eye was performed in 48 (61%) eyes, bilateral
enucleation in 24 (30%) eyes, and exenteration in three (4%) eyes in
the early years of this study. Additional exenteration was done in
one eye due to orbital recurrence of RB after 4 years of initial
enucleation. Two eyes (2.5%) received local laser treatment in Korea
and China, and two (2.5%) cases received systemic intravenous
chemotherapy only and the tumors were stable with partial
regression (Table 2).
Figure 1. Annual retinoblastoma incidence per 10,000 live births in Mongolia.
Table 1
Characteristics of patients with retinoblastoma (1987 to January 2014, Mongolia).
Characteristics No. of cases %
Age at diagnosis (Mean ± SD)
Bilateral 13.1 ± 12.8
Unilateral 24.5 ± 15.8
Sex
Male 32 50
Female 32 50
Laterality
Unilateral 49 77
Bilateral 15 23
Presenting signs
Leukocoria 50 78
Strabismus 24 38
Secondary glaucoma 21 33
Hyphema 7 11
Orbital cellulitis 7 11
Spread of tumor
Intracranial extension 1 2
Extraocular extension 3 5
Orbital recurrence 1 2
Family history
Yes 1 2
No 63 98
SD ¼ standard deviation.
Figure 2. Presenting sign of extraocular extension of retinoblastoma in a Mongolian
patient aged 4 years. This patient passed away due to late diagnosis.
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Histopathological examination was performed in 72/79 (91%)
eyes after enucleation, and undifferentiated type was found in 34
(47%) eyes. Optic nerve inﬁltration was present in ﬁve (7%) eyes,
rosettes (well-differentiated) in four (5.5%) eyes, calciﬁcation in
four (5.5%) eyes, and necrosis and hemorrhage in one eye each. The
reminder 23 (32%) was unclear due to no information on the pa-
tient's chart.
3.10. Immunohistochemical analysis
Enucleated eyes of ﬁve children were used for histologic and
immunochemical analysis study. Histologically, four tumors
(80%) were classiﬁed as undifferentiated RB and one (20%) case
was well-differentiated RB on the basis of the presence of areas
containing FlexnereWintersteiner rosettes and ﬂeurettes. In ﬁve
cases with an immunohistochemical analysis of the eye spec-
imen, NSE-, Ki-67 protein-, and B-cell lymphoma 2 (Bcl-2)-pos-
itive cells were found in all ﬁve (100%) cases, and Rb protein
was detected in three (60%) cases. Vimentin was detected in
two cases, glial ﬁbrillary acidic protein in three cases, P-53 in
two cases, and S-100 in three cases. The results are shown in
Table 3.
Pathologically, two of ﬁve (40%) cases demonstrated nerve
involvement, three (60%) cases had retinal pigment epithelium
involvement, two (40%) cases had choroid involvement, and two
(40%) cases had a calciﬁcation. Detailed information of the immu-
nohistochemistry is given in Table 3.
3.11. Follow-up
At the time of last follow-up, 52 (81%) patients were alive, ﬁve
(8%) patients were dead, and seven (11%) patients had been lost to
follow-up or unknown vital status. The mean follow-up period
was 121.5 months (range, 12e360 months) (Figure 4). The longest
follow-up period was 27 years in a male with bilateral RB, and his
son was born with inherited bilateral RB. Enucleation of father's
right eye and left eye was done at the age of 3 months and
44 months, respectively. His son also received bilateral enucle-
ation in the right eye at the age of 2 months and in the left eye at
the age of 61 months. Five (8%) patients died due to a delayed
diagnosis of RB with the presentation of extra extension and
intracranial spread.
The 1-, 5-, and 10-year survival rates of the RB cases were 95.3%
(61/64), 82.8% (53/64), and 81.1% (52/64), respectively.
Figure 3. Recurrence of retinoblastoma. (A) Orbital recurrence of retinoblastoma, 4 years after the initial enucleation in a 5-year-old girl. (B) The exenteration specimen was
measured to be of 47  53  39 mm3. The tumor invaded the surrounding connective tissues and muscles. The superior surgical margin was not tumor free and completely resected.
Histopathological examination disclosed an undifferentiated recurrent retinoblastoma. The patient died 5 months after the exenteration.
Table 2
Mode of treatment in retinoblastoma cases.
No. of eyes %
Unilateral enucleation 48 61
Bilateral enucleation 24 30
Unilateral exenteration 3 4
Laser photocoagulation therapy 2 2.5
Systemic intravenous chemotherapy 2 2.5
0.
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75
1.
00
0 100 200 300 400
Analysis time
Kaplan–Meier survival estimate
Mean follow-up: 121.5 mo
Figure 4. Mean follow-up period was 121.5 months
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Our study shows that the mean age of RB patients at presenta-
tion was 24.5 months. The age of diagnosis was earlier in bilateral
cases (13.1 months) than in unilateral cases (28.1 months). The
common clinical presentations were leukocoria (78%), strabismus
(38%), and glaucoma (33%). Sixty-one (95%) patients were diag-
nosed with Classiﬁcation D or worse when they were presented to
us. Chemotherapy has achieved an important role in the manage-
ment of intraocular RB. We have been using the standard intrave-
nous chemotherapy (etopside, carboplatin, and vincristine) for
intraocular RB since 2012 in Mongolia. Prior to 2012, a different
guideline was used for the RB treatment in Mongolia, which
included chemotherapy and external beam radiation therapy. ThereTable 3
Histopathologic and Immunohistochemical results of ﬁve patients who have received en
Case/ID Case 1/0033 Case 2/0034
Code X-1279 X-797
Pathological type Undifferentiated Undifferentiated
Nerve involvement NA þ
RPE involvement þ þ
Choroid involvement þ þ
Calciﬁcation  þ
Immunohistochemistry
RB þ þ
Bcl-2 þ þ
Ki-67 þ þ
NSE þ þ
Vimentin /Stromal cells(þ) þ
GFAP þ þ
P-53 þ 
S100 þ þ
Bcl-2¼ B-cell lymphoma 2; GFAP¼ glial ﬁbrillary acidic protein; Ki-67¼ protein in huma
67); NSE ¼ neuron-speciﬁc enolase; P-53 ¼ tumor protein p53; S-100 ¼ low-molecula
Vimentin ¼ an immunohistochemical study of vimentin.is a need to compare the clinical outcomes between patients
diagnosed before 2012 and those diagnosed after 2012. Enucleation
is still frequently used in advanced cases, including large tumors,
neovascular glaucoma, pars plana tumor seeding, anterior chamberucleation.
Case 3/0037 Case 4/0042 Case 5/0053
X-171 X-27 X-1345
Differentiated Undifferentiated Undifferentiated
 þ NA
 þ 
 NA 
NA  þ
 þ þ
þ þ þ
þ þ þ
þ þ þ
/Stromal cells(þ) þ þ
/Stromal cells(þ)  þ
þ  þ
 NA þ
ns that is encoded by theMKI67 gene (antigen identiﬁed by monoclonal antibody Ki-
r-weight protein; RB ¼ retinoblastoma protein; RPE ¼ retinal pigment epithelium;
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with no expectation of useful vision.
Late diagnosis is fairly common in our cases series; destructive
procedures such as unilateral and bilateral enucleations and
exenteration were performed in 75 (95%) eyes. Globe salvage and
preservation of vision were only 5%, much lower than the data
reported from developed countries.5e10 Our data have shown that
RB in Mongolia is frequently diagnosed at late stages and the out-
comes are poor. These data show that there are room for
improvement regarding the awareness of RB and its early treat-
ment in Mongolia.
In studies conductedworldwide, there are no gender differences
in RB, the average age at diagnosis is 18 months, and the vast ma-
jority become clinically apparent before the age of 3 years.3,5,7,11e13
In most of the developed countries, patients with bilateral tumors
present earlier than those with unilateral involvement.1,14 The age
at initial diagnosis is: 23 months in China and 84% of them were
diagnosed younger than 3 years, 25 months in Brazil, 25 months in
Turkey, 23.9 months in India, 28.5 months in Iran, and 18months in
America.3,5,7,11e13 In our case series, the median age of diagnosis
was 24.5 months in Mongolia, similar to prior reports from other
countries.
Leukocoria is the most common presenting sign of RB, followed
by strabismus, across the world (Table 4). The ﬁgures vary from
country to country, and from time to time in the same country. This
could probably be due to geographical variation of the disease,
awareness of the disease among public, availability of medical fa-
cilities in that country, and the number of patients examined. The
pattern of presentations in our study is consistent with many
studies from different parts of the world. In addition to the above,
Abramson et al5 reported many uncommon/rare presenting signs
such as inﬂammatory signs, proptosis, orbital cellulitis, hyphema,
anisocoria, heterochromia iridis, vitreous hemorrhage, and micro-
phthalmos RB. However, proptosis as the presenting sign at the
time of diagnosis was reported in high frequency from some of the
developing countries such as Nigeria (84.6%),20 Korea (80%),9
Pakistan (52.8%),19 Nepal (44.2%),18 Thailand (26.7%),16 and India
(25.3%).21 In our studies, presenting signs of leukocoria, strabismus,
and secondary glaucoma are more common and were seen in 78%,
38%, and 33% of our patients, respectively. Proptosis was a rare
presenting sign, seen in only 5% of our patients. Bilateral RB was
seen in 23.4% of patients in our case series, which was lower than
the ﬁgures reported from China (32%),3 Korea (31.4%),9 USA
(41.5%),5 Australia (41%),6 India (37.2%),21 and Thailand (36.7%).16
Saving patients' life is the primary goal of treatment in RB.
Enucleation and exenteration are effective methods to achieve that
goal. However, now with the introduction of local treatments, suchTable 4
Comparative frequency of common presenting signs of retinoblastoma in different parts
Authors Year Country No. of pa
Abramson et al5 1998 USA 1265
Chantada et al15 1999 Argentina 95
Patikulsila and Patikulsila16 2001 Thailand 30
Kao et al17 2002 Taiwan 96
Berman et al6 2007 Australia 165
Shanmugam et al13 2005 India 355
Badhu et al18 2005 Nepal 43
Ozkan et al11 2006 Turkey 141
Chung et al9 2008 South Korea 70.0
Rai et al19 2009 Pakistan 53
Bonanomi et al7 2009 Brazil 28
Naseripour et al12 2009 Iran 105
Zhao et al3 2011 China 470
Present study 2014 Mongolia 64as laser and cryotherapy, intravitreal chemotherapy, chemo-
reduction, and selective ophthalmic artery infusion, ocular preser-
vation rates have become much higher. Some patients even enjoy
good vision after treatment. Saving eyes and vision requires disease
recognition before leukocoria, as demonstrated by better ocular
salvage rates among patients who had a positive family history and
received clinical surveillance via early and routine dilated fundu-
scopic examinations by an ophthalmologist.5
Early diagnosis and prompt treatment are important factors in
achieving high survival rates. In developing countries, late referral
has been implicated as an important factor related to prognosis of
RB patients.15 In our analysis of 79 eyes with RB, globe salvage and
preservation of vision was observed in four (5%) eyes, much lower
than that for developed countries. As for survival, 53 (83%) patients
lived, seven (11%) patients had unknown vital status, and four (6%)
patients died. In developing countries, poor education, lower so-
cioeconomic conditions, and inefﬁcient health care systems result
in delayed diagnosis and suboptimal care. Furthermore, it is seldom
possible to achieve the complexity of multidisciplinary care
required. While ocular salvage is a priority in the Western world,
death from RB is still a major problem in developing countries.22
Worldwide, the incidence of RB is recorded to be about 11 cases
per million children younger than 5 years. A more commonly used
estimate is one case of RB per 18,000e30,000 live births, depending
on the nation. An estimated 250e500 new cases of RB occur in the
United States yearly.5 The average incidence of RB varies by race or
geographic location, but the average incidence is approximately
one in 15,000 newborns.11,17,20,23 In our studies, the estimated
incidence of RB was about one in 32,000e33,000 live births in
Mongolia, which is slightly lower than the internationally reported
incidence. This retrospective review may provide limited infor-
mation on some patients who might have obtained medical help in
other countries with no registration in the National Center for
Maternal Health, leading to an underestimation of the incidence.
However, all pediatric patients who sought medical help in other
countries usually ﬁrst visited the center and were registered here
because of reimbursement mechanisms of some medical fees by
insurance. Therefore, the chance of being unregistered or not
visiting the center is rare.
The incidence of RB is not distributed equally around the world.
Whether these geographical variations are due to ethnic or socio-
economic factors is not well known. However, the fact that even in
industrialized countries an increased incidence of RB is associated
with poverty and low levels of maternal education suggests a role
of the environment.2 In our study, 68% of RB cases were diagnosed
from rural areas where the socioeconomic status is lower than the
urban areas in Mongolia.of the world.
tients Leukocoria (%) Strabismus (%) Proptosis (%)
56.1 23.6 0.5
81 14.3 d
60 10.0 26.7
78.1 12.5 16.7
53.3 26.0 d
74.6 6.2 1.1
32.5 d 44.2
82.2 9.2 7.8
80.0 8.5 1.4
22.6 5.6 52.8
75.0 10.7 3.6
64.8 28.2 d
73 55 d
78.1 37.5 4.6
T. Chuluunbat et al. / Taiwan Journal of Ophthalmology 6 (2016) 79e8484The Rb protein is a tumor suppressor protein, which when
inactivated results in the development of RB cancer. In our series,
three of ﬁve cases (60%) were detected to express Rb protein on
immunohistochemical analysis. Sun et al24 found that NSE is a
substance that has been detected in patients with certain tumors,
and stained strongly positive in undifferentiated tumor cells and
weakly positive in rosettes and ﬂeurettes in most of the cases (21/
27). In our study, NSE-positive cells were found in all ﬁve RB cases,
and four of ﬁve (80%) cases were classiﬁed to have undifferentiated
RB cells.
Karim et al25 revealed that S-100 protein, glial ﬁbrillary acidic
protein, vimentin, NSE were positive only for glial elements, and
NSE and bcl-2 for almost all tumor cells. These means that the
majority of RBs are sporadic and composed of neuron-committed
cells. In our study, NSE- and Bcl-2-positive cells were found in all
ﬁve RB (100%) cases.
In the current study, undifferentiated tumor cells were the most
common type of histopathological ﬁndings and were positive in
47% of advanced enucleated cases. Kashyap et al26 identiﬁed poorly
differentiated RB in 80.3% and well-differentiated RB in 19.7% of
609 eyes enucleated for advanced intraocular RB. Well-
differentiated tumors were found to present earlier (median,
1.2 years) than poorly differentiated tumors (median, 2.5 years) and
had better prognosis than the undifferentiated ones.
This study has several limitations. The retrospective nature of
the study, incomplete clinical data of some patients, and the
immunohistochemical analysis data were available only for ﬁve
patients, which could compromise the study outcome. Computed
tomography scanning and magnetic resonance imaging were not
introduced until 2001 in Mongolia. Cryotherapy, laser, or trans-
pupillary thermal therapy was not available in the whole country.
Selective ophthalmic arterial infusion has not yet been introduced
at our center. Furthermore, RB is a paramount example of multi-
disciplinary care in a pediatric cancer, which is difﬁcult to achieve
in a developing country like Mongolia.22
In conclusion, patients with RB from rural areas are more
frequently diagnosed at late stages in Mongolia. This shows the
importance of regular screening programs for early detection of
tumors among children aged younger than 3 years. In addition,
most Mongolian children with RB usually present with leukocoria
noted by parents, rather than being detected by routine pediatric
screening via the red reﬂex test performed by an ophthalmologist.
Further efforts are needed to detect early stages of RB and render
better treatments to increase survival, ocular preservation, and
even functional vision of the patients in Mongolia.References
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